SAINT LOUIS–( COMPANY CORD)– Cofactor Genomics, Inc., a clinical-stage firm linking the accuracy medication space by translating RNA, revealed the magazine of their logical recognition research of the OncoPrism ®- HNSCC examination on the heels of its effective scientific recognition and Medicare Repayment. OncoPrism-HNSCC forecasts take advantage of immune checkpoint preventions (ICIs) for individuals with recurrent/metastatic squamous cell cancer of the head and neck, a seriously required device for a patie
发布者：Dr.Durant，转转请注明出处：https://robotalks.cn/cofactor-genomics-publishes-analytical-validation-of-oncoprism-hnscc-highlighting-robustness-of-the-ai-powered-rna-test-in-predicting-cancer-patient-response-to-immunotherapy/
